drugset / Trial / NCT02233790

Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI

NCT02233790 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The patients with acute myocardial infarction (AMI) present high mortality and morbidity rate,even treated with stenting in the blocked heart vessels. The appearance of no-reflow is common after re-opening of the blocked vessel. The no-reflow were commonly attributed to tiny blockage in coronary micro-vasculature by thrombus and spasm of the micro-vessel during stenting. An agent with more effective anti-clotting and micro-vessel dilation would be helpful to solve the issue of no-reflow. Ticagrelor was demonstrated to be a potent platelet inhibitor and a potent micro-vessel dilator which can influence metabolism of adenosine, a endogenous potent small vessel dilator. This study is to test the effectiveness of ticagrelor on improving reperfusion and minimizing the myocardial infarct size after PPCI in patients with AMI.

Timeline

Start
2014-12
Primary completion
2016-09
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg —
Subject Ticagrelor Small molecule 90 mg —

Indications